RxSight, Inc. (NASDAQ:RXST – Get Free Report) insider Eric Weinberg sold 2,041 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $6.96, for a total value of $14,205.36. Following the transaction, the insider directly owned 200,348 shares in the company, valued at approximately $1,394,422.08. This represents a 1.01% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
RxSight Stock Performance
Shares of RXST opened at $7.03 on Thursday. RxSight, Inc. has a fifty-two week low of $4.48 and a fifty-two week high of $13.22. The firm has a market cap of $292.40 million, a price-to-earnings ratio of -6.22 and a beta of 1.16. The firm has a 50 day moving average price of $5.95 and a 200-day moving average price of $6.35.
RxSight (NASDAQ:RXST – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. The company had revenue of $33.74 million for the quarter, compared to analysts’ expectations of $32.55 million. RxSight had a negative net margin of 36.80% and a negative return on equity of 17.35%. As a group, equities research analysts predict that RxSight, Inc. will post -1.01 earnings per share for the current year.
Hedge Funds Weigh In On RxSight
Wall Street Analyst Weigh In
Several analysts have weighed in on the company. Weiss Ratings downgraded RxSight from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, June 11th. Wall Street Zen cut shares of RxSight from a “hold” rating to a “sell” rating in a report on Saturday, August 29th. Bank of America decreased their target price on shares of RxSight from $8.00 to $6.50 and set an “underperform” rating on the stock in a research note on Tuesday, July 7th. UBS Group increased their price target on shares of RxSight from $5.50 to $6.30 and gave the company a “neutral” rating in a research report on Thursday, August 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $11.00 price target on shares of RxSight in a report on Tuesday, July 7th. Two research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Reduce” and a consensus price target of $8.37.
Check Out Our Latest Report on RXST
RxSight Company Profile
RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.
Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.
Featured Articles
- Five stocks we like better than RxSight
- Striking Oil: How the U.S. Play for Venezuela Fuels Supermajors
- J.M. Smucker Stock’s Rally Has More Than Tariffs Behind It
- Wendy’s Rally Fades After Trian Steps Back: Was It Ever Real?
- GitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse Test
Receive News & Ratings for RxSight Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RxSight and related companies with MarketBeat.com's FREE daily email newsletter.
